US Vaccine maker Novavax says its vaccine shows 90% overall efficacy
The vaccine also has 100% protection against moderate and severe disease in Phase 3 trials
Novavax has a tie-up with Serum Institute of India (SII) to manufacture vaccines for India
Novavax says the vaccine has 93% efficacy against predominantly circulating variants of concern and variants of interest
The company intends to file for regulatory authorisations in the third quarter
SII will be able to launch the vaccine in India if Novavax gets Emergency Use Authorisation in the US
